BR112018003110A2 - nanopartículas terapêuticas compreendendo um agente terapêutico e métodos de fabricação e uso dos mesmos - Google Patents

nanopartículas terapêuticas compreendendo um agente terapêutico e métodos de fabricação e uso dos mesmos

Info

Publication number
BR112018003110A2
BR112018003110A2 BR112018003110A BR112018003110A BR112018003110A2 BR 112018003110 A2 BR112018003110 A2 BR 112018003110A2 BR 112018003110 A BR112018003110 A BR 112018003110A BR 112018003110 A BR112018003110 A BR 112018003110A BR 112018003110 A2 BR112018003110 A2 BR 112018003110A2
Authority
BR
Brazil
Prior art keywords
therapeutic
nanoparticles
methods
manufacturing
therapeutic agent
Prior art date
Application number
BR112018003110A
Other languages
English (en)
Inventor
Horhota Allen
Simmons Matthew
Boylan Nicholas
Joshi Ujjwal
Song Young-Ho
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of BR112018003110A2 publication Critical patent/BR112018003110A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

a presente invenção refere-se geralmente a nanopartículas compreendendo um agente de escape endo-lisossomal, um ácido nucleico e um polímero. outros aspectos incluem métodos de fabricação e uso dessas nanopartículas.
BR112018003110A 2015-08-21 2016-08-19 nanopartículas terapêuticas compreendendo um agente terapêutico e métodos de fabricação e uso dos mesmos BR112018003110A2 (pt)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201562208361P 2015-08-21 2015-08-21
US201562238400P 2015-10-07 2015-10-07
US201562242515P 2015-10-16 2015-10-16
US201662279295P 2016-01-15 2016-01-15
US201662349377P 2016-06-13 2016-06-13
PCT/US2016/047799 WO2017034991A1 (en) 2015-08-21 2016-08-19 Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same

Publications (1)

Publication Number Publication Date
BR112018003110A2 true BR112018003110A2 (pt) 2018-09-25

Family

ID=58100966

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018003110A BR112018003110A2 (pt) 2015-08-21 2016-08-19 nanopartículas terapêuticas compreendendo um agente terapêutico e métodos de fabricação e uso dos mesmos

Country Status (12)

Country Link
US (3) US20170049709A1 (pt)
EP (1) EP3337516A4 (pt)
JP (1) JP6983150B2 (pt)
KR (1) KR20180037053A (pt)
CN (1) CN108348506A (pt)
AU (1) AU2016313439B2 (pt)
BR (1) BR112018003110A2 (pt)
CA (1) CA2995990C (pt)
HK (1) HK1256704A1 (pt)
IL (1) IL257318A (pt)
RU (1) RU2018105118A (pt)
WO (1) WO2017034991A1 (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017034991A1 (en) 2015-08-21 2017-03-02 Pfizer Inc. Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same
US20190185854A1 (en) * 2016-06-23 2019-06-20 Massachusetts Institute Of Technology Micro-RNA Delivery Compositions, Devices, and Methods
WO2018134310A1 (en) 2017-01-19 2018-07-26 Universiteit Gent Molecular adjuvants for enhanced cytosolic delivery of active agents
WO2018175445A1 (en) * 2017-03-20 2018-09-27 Northwestern University Poly(lactic-co-glycolic acid) (plga) spherical nucleic acids
WO2018232357A1 (en) 2017-06-15 2018-12-20 Modernatx, Inc. Rna formulations
US20200115688A1 (en) * 2017-08-15 2020-04-16 The Regents Of The University Of California Compositions and methods for enhancing genome editing
EP3675817A1 (en) 2017-08-31 2020-07-08 Modernatx, Inc. Methods of making lipid nanoparticles
KR102089737B1 (ko) * 2017-11-01 2020-03-16 한국화학연구원 에씨탈로프람을 함유한 미립구형 서방출 주사제 및 그의 제조방법
CA3093968A1 (en) * 2018-03-15 2019-09-19 KSQ Therapeutics, Inc. Gene-regulating compositions and methods for improved immunotherapy
CN112889835B (zh) * 2018-06-22 2022-06-07 华东师范大学 新的食品防腐剂及其制备方法和应用
US11696902B2 (en) 2018-08-14 2023-07-11 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
US11610660B1 (en) 2021-08-20 2023-03-21 AltaThera Pharmaceuticals LLC Antiarrhythmic drug dosing methods, medical devices, and systems
JP2022501367A (ja) * 2018-09-20 2022-01-06 モデルナティエックス インコーポレイテッドModernaTX, Inc. 脂質ナノ粒子の調製及びその投与方法
WO2020237227A1 (en) 2019-05-22 2020-11-26 Massachusetts Institute Of Technology Circular rna compositions and methods
CN110193087B (zh) * 2019-06-12 2022-02-08 山西医科大学 一种肿瘤微环境响应型诊疗一体化纳米探针及其制备方法
WO2021113761A1 (en) * 2019-12-05 2021-06-10 Board Of Regents, The University Of Texas System Exosomes-based therapy for liver fibrosis and other diseases associated with fibrosis
CN111057068B (zh) * 2019-12-10 2022-03-08 曲阜师范大学 检测神经鞘氨醇葡萄糖苷和神经鞘氨醇半乳糖苷的多通道质谱衍生试剂及其制备方法与应用
CN111057067B (zh) * 2019-12-10 2022-02-25 曲阜师范大学 一种检测神经鞘氨醇己三糖苷的多通道质谱衍生试剂及其制备方法与应用
US11344503B2 (en) * 2019-12-13 2022-05-31 Halo Science LLC Cariprazine release formulations
CN111249469B (zh) * 2020-03-20 2022-03-08 临沂大学 一种能够溶酶体逃逸的肽纳米颗粒及其制备方法和应用
CN111821303B (zh) * 2020-09-04 2021-06-18 郑州大学 沃替西汀及其盐在制备抗肿瘤药物中的应用
US11452690B1 (en) 2021-01-27 2022-09-27 ECI Pharmaceuticals, LLC Oral liquid compositions comprising amlodipine besylate and methods of using the same
CN117337168A (zh) * 2021-04-01 2024-01-02 渤健马萨诸塞州股份有限公司 向中枢神经系统的核酸递送
WO2023108082A1 (en) * 2021-12-09 2023-06-15 Materia Therapeutics Inc. Cancer treatment using ketotifen in combination with a checkpoint inhibitor
WO2023114375A2 (en) * 2021-12-16 2023-06-22 Alveolus Bio, Inc. Inhalable or ingestible lactic acid compositions for the treatment of chronic lung disease
CN115165819A (zh) * 2022-05-27 2022-10-11 天津科技大学 一种快速定量分析芦丁的荧光分子印迹光子晶体凝胶条的制备方法及应用
WO2024003363A1 (en) 2022-06-30 2024-01-04 Universiteit Gent Cationic amphiphilic compound-based nanoparticle compositions
WO2024102677A1 (en) 2022-11-08 2024-05-16 Orna Therapeutics, Inc. Circular rna compositions

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5587361A (en) 1991-10-15 1996-12-24 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
US5599797A (en) 1991-10-15 1997-02-04 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
TW244371B (pt) 1992-07-23 1995-04-01 Tri Clover Inc
EP1737879B1 (en) 2004-04-19 2012-10-10 Archemix LLC Aptamer-mediated intracellular delivery of therapeutic oligonucleotides
US8865216B2 (en) * 2007-08-03 2014-10-21 National Institutes Of Health (Nih) Surface-modified nanoparticles for intracellular delivery of therapeutic agents and composition for making same
US20090312402A1 (en) * 2008-05-20 2009-12-17 Contag Christopher H Encapsulated nanoparticles for drug delivery
CN102099016A (zh) * 2008-06-16 2011-06-15 佰恩德生物科学股份有限公司 载药的聚合物纳米微粒及其制备和使用方法
JP2012501965A (ja) * 2008-06-16 2012-01-26 バインド バイオサイエンシズ インコーポレイテッド 薬剤を装填したポリマーナノ粒子及びその製造方法と使用方法
US20150056300A1 (en) * 2010-10-22 2015-02-26 Bind Therapeutics, Inc. Therapeutic nanoparticles with high molecular weight copolymers
WO2012166923A2 (en) * 2011-05-31 2012-12-06 Bind Biosciences Drug loaded polymeric nanoparticles and methods of making and using same
US10172956B2 (en) * 2012-10-26 2019-01-08 Vanderbilt University Polymeric nanoparticles
RS58576B1 (sr) 2012-10-31 2019-05-31 Ionis Pharmaceuticals Inc Tretman raka
WO2015058111A1 (en) * 2013-10-17 2015-04-23 The Brigham And Women's Hospital, Inc. Cationic nanoparticles for co-delivery of nucleic acids and thereapeutic agents
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
JP6573895B2 (ja) * 2014-02-13 2019-09-11 ファイザー・インク 治療剤を含む治療用ナノ粒子ならびにその製造方法および使用方法
WO2017034991A1 (en) * 2015-08-21 2017-03-02 Pfizer Inc. Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same

Also Published As

Publication number Publication date
US20190091164A1 (en) 2019-03-28
WO2017034991A1 (en) 2017-03-02
CA2995990C (en) 2021-11-16
EP3337516A1 (en) 2018-06-27
IL257318A (en) 2018-06-28
US20170049709A1 (en) 2017-02-23
EP3337516A4 (en) 2019-04-03
CN108348506A (zh) 2018-07-31
RU2018105118A3 (pt) 2019-09-23
HK1256704A1 (zh) 2019-10-04
RU2018105118A (ru) 2019-09-23
JP2018528194A (ja) 2018-09-27
US10952972B2 (en) 2021-03-23
US20210259982A1 (en) 2021-08-26
AU2016313439B2 (en) 2019-10-03
AU2016313439A1 (en) 2018-02-22
JP6983150B2 (ja) 2021-12-17
CA2995990A1 (en) 2017-03-02
KR20180037053A (ko) 2018-04-10

Similar Documents

Publication Publication Date Title
BR112018003110A2 (pt) nanopartículas terapêuticas compreendendo um agente terapêutico e métodos de fabricação e uso dos mesmos
CY1122329T1 (el) Anti-siglec-8 αντισωματα και μeθοδοι χρhσεως αυτων
CL2018000813A1 (es) Conjugados de anticuerpo-fármaco de pirrolobenzodiazepina y métodos de uso.
BR112015022625A2 (pt) micromatrizes para entrega de agente terapêutico e métodos de uso
BR112016006319A2 (pt) inibidores de irak e usos dos mesmos
BR112018003019A2 (pt) vacinas terapêuticas contra hpv18
IL254813B (en) Sustained-release injectable formulations containing isoxazoline active agent and methods and uses thereof
CY1123947T1 (el) Βελτιστοποιημενος υποκινητης rpe65 και βελτιστοποιημενες κωδικοποιητικες αλληλουχιες
BR112018005755A2 (pt) benzamidas substituídas com isoxazolina e análogos como inseticidas.
BR112019004911A2 (pt) oligonucleotídeos modificados e métodos de uso
BR112017013012A2 (pt) compostos de indenil, composições farmacêuticas e usos médicos destes
BR112016017609A2 (pt) Composição, e, processo
CY1121000T1 (el) Sirna και χρηση αυτου σε μεθοδους και συνθεσεις για την θεραπεια ή/και προληψη οφθαλμικων καταστασεων
MX2018005085A (es) Nanoparticulas terapeuticas que comprenden un agente terapeutico y metodos de fabricacion y uso de las mismas.
CY1125031T1 (el) Μεθοδος για γενετικη θεραπεια χρησιμοποιωντας τον ιο aav-xbp1s/gfp και χρηση αυτης στην προληψη και τη θεραπεια της αμυοτροφικης πλευρικης σκληρυνσης
BR112017014416A2 (pt) sal de mangiferina-6-o-berberina e método de preparação e uso do mesmo
MX2016004078A (es) Formulacion de atazanavir y cobicistat para el tratamiento del virus de inmunodeficiencia humana (vih).
DK3294756T3 (da) Retroviral partikel, omfattende mindst to forskellige indkapslede, ikke-virale RNA'er
MA42611A (fr) Traitement combiné comprenant l'administration de 2-amino-3,5,5-trifluoro-3,4,5,6-tétrahydropyridines
EP3295175A4 (en) Targeted protein contrast agents, methods of making, and uses thereof
CY1122708T1 (el) Ενωσεις οξα-διαζασπειρο με δραση εναντι του πονου
IL270326B (en) Tdr with new preparations, combinations and their methods
MX2017009313A (es) Formulaciones intravenosas de baclofeno y metodos de tratamiento.
BR112017002915A2 (pt) processo para manufaturar um dispositivo de uso médico customizável e dispositivo obtido pelo dito processo
FR3041605B1 (fr) Coupole de rotor, rotor et giravion

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements